Related Experiment Video
Updated: Nov 26, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Pomalidomide and dexamethasone in myelomatous pleural effusion
Isin Yagmur Comba1, Anthony Chahin2, Hiffsa Taj2
1Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, Florida, USA yagmurcomba@gmail.com.
Abstract:
Myelomatous pleural effusion (MPE) is an uncommon clinical entity and occurs in less than 1% of all patients with multiple myeloma. MPE indicates a progression of disease, therefore is associated with a poor prognosis and estimated median survival of <3 months. Treatment of MPE is challenging, and the data regarding the role of novel agents lack in the literature. Herein, we report a relapsed IgA myeloma case of a patient presenting with MPE, who was treated with pomalidomide with a very good partial response.
Related Concept Videos
Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
Pleural Effusion I: Introduction
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Pneumothorax-II
Clinical Manifestations:
Pericarditis III: Medical Management

